Circulating t-PA antigen predicts major adverse coronary events in patients with stable coronary artery disease – a 13-year follow-up

Alexander Niessner; Senta Graf; Mariam Nikfardjam; Walter S. Speidl; Renate Huber-Beckmann; Gerlinde Zorn; Johann Wojta; Kurt Huber

doi:10.1160/TH02-10-0185

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2003; 90(02): 344-350
DOI: 10.1160/TH02-10-0185

Vascular Development and Vessel Remodelling

Schattauer GmbH

Circulating t-PA antigen predicts major adverse coronary events in patients with stable coronary artery disease – a 13-year follow-up

Authors

Alexander Niessner

¹Departments of Cardiology, Wilhelminen-Hospital, Vienna, Austria
Senta Graf

¹Departments of Cardiology, Wilhelminen-Hospital, Vienna, Austria
Mariam Nikfardjam

¹Departments of Cardiology, Wilhelminen-Hospital, Vienna, Austria
Walter S. Speidl

¹Departments of Cardiology, Wilhelminen-Hospital, Vienna, Austria
Renate Huber-Beckmann

²Vascular Biology and Thrombosis Research, University of Vienna, Wilhelminen-Hospital, Vienna, Austria
Gerlinde Zorn

¹Departments of Cardiology, Wilhelminen-Hospital, Vienna, Austria
Johann Wojta

¹Departments of Cardiology, Wilhelminen-Hospital, Vienna, Austria
Kurt Huber

¹Departments of Cardiology, Wilhelminen-Hospital, Vienna, Austria

³Department of Cardiology and Emergency Medicine, Wilhelminen-Hospital, Vienna, Austria

Abstract

Summary

Thrombus formation after rupture of an atherosclerotic plaque plays a crucial role in coronary artery disease (CAD). A decreased endogenous fibrinolytic system and prothrombotic factors are supposed to influence coronary thrombosis. It was our aim to investigate the predictive value of tissue plasmino-gen activator (t-PA) antigen, von Willebrand Factor, Lipoprotein (a) and anti-cardiolipin antibodies for major adverse coronary events in patients with stable CAD in a prospective cohort study of more than 10 years.

We observed 141 patients with angiographically proven CAD for a median follow-up period of 13 years. t-PA antigen was the only marker predicting coronary events (logistic regression, p = 0.044) with a poor prognosis for patients in the 5^th quintile with an odds ratio of 7.3 (compared to the 1^st quintile). The odds ratio even increased to 10.0 for coronary events associated with the “natural course” of CAD excluding events due to restenosis. t-PA antigen had a slightly higher prognostic power (ROC curve; AUC = 0.69) than fasting glucose (AUC = 0.68) and cholesterol (AUC = 0.67). Triglycerides influenced plasma levels of t-PA antigen (regression, p < 0.001). The predictive value of t-PA antigen remained significant after adjustment for inflammation (logistic regression, p = 0.013) and extent of CAD (p = 0.045) but disappeared adjusting for insulin resistance (p = 0.12).

In conclusion t-PA antigen predicted coronary events during a very long-term follow-up with a comparable prognostic power to established cardiovascular risk factors. Markers of insulin resistance influenced t-PA antigen and its predictive value.

Part of this paper was originally presented at the joint meetings of the 16th International Congress of the International Society of Fibrinolysis and Proteolysis (ISFP) and the 17th International Fibrinogen Workshop of the International Fibrinogen Research Society (IFRS) held in Munich, Germany, September 2002.

Keywords

Tissue plasminogen activator - endogenous fibrinolytic system - coronary artery disease - long-term follow-up - prospective cohort study

Full Text

References

References
1 Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310 (18) 1137-40.
2 Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92 (03) 657-71.
3 Farb A, Burke AP, Tang AL. et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996; 93 (07) 1354-63.
4 Davies MJ, Bland JM, Hangartner JR. et al. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J 1989; 10 (03) 203-8.
5 Frink RJ. Chronic ulcerated plaques: new insights into the pathogenesis of acute coronary disease. J Invasive Cardiol 1994; 6 (05) 173-85.
6 Rioufol G, Finet G, Ginon I. et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation 2002; 106 (07) 804-8.
7 Moss AJ, Goldstein RE, Marder VJ. et al. Thrombogenic factors and recurrent coronary events. Circulation 1999; 99 (19) 2517-22.
8 Fuster V, Badimon JJ, Badimon L. Clinical-pathological correlations of coronary disease progression and regression. Circulation 1992; 86 (Suppl. 06) Suppl III1-11.
9 Falk E. Coronary thrombosis: pathogenesis and clinical manifestations. Am J Cardiol 1991; 68 (07) 28B-35B.
10 Lupu F, Bergonzelli GE, Heim DA. et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13 (07) 1090-100.
11 Huber K, Resch I, Stefenelli T. et al. Plasminogen activator inhibitor-1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis. Thromb Haemost 1990; 63 (03) 336-9.
12 Olofsson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angio-graphically verified coronary artery disease. Eur Heart J 1989; 10 (01) 77-82.
13 Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost 1999; 82 (02) 259-70.
14 Thogersen AM, Jansson JH, Boman K. et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrin-olytic system as an independent primary risk factor. Circulation 1998; 98 (21) 2241-7.
15 Juhan-Vague I, Pyke SD, Alessi MC. et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94 (09) 2057-63.
16 Ridker PM, Vaughan DE, Stampfer MJ. et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341 8854 1165-8.
17 Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991; 12 (02) 157-61.
18 Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993; 88 5 Pt 1 2030-4.
19 Wiman B, Andersson T, Hallqvist J. et al. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 2000; 20 (08) 2019-23.
20 Held C, Hjemdahl P, Rehnqvist N. et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm. Circulation 1997; 95 (10) 2380-6.
21 Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342 (24) 1792-801.
22 Huber K, Christ G, Wojta J, Gulba D. Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. Thromb Res 2001; 103 (Suppl. 01) Suppl S7-19.
23 Goto S, Sakai H, Goto M. et al. Enhanced shear-induced platelet aggregation in acute myocardial infarction. Circulation 1999; 99 (05) 608-13.
24 Thompson SG, Kienast J, Pyke SD. et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332 (10) 635-41.
25 Karmansky I, Gruener N. Structure and possible biological roles of Lp(a). Clin Biochem 1994; 27 (03) 151-62.
26 Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102 (10) 1082-5.
27 Berg K, Dahlen G, Christophersen B. et al. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 1997; 52 (05) 254-61.
28 Levine JS, Branch DW, Rauch J. The anti-phospholipid syndrome. N Engl J Med 2002; 346 (10) 752-63.
29 Wilson WA, Gharavi AE, Koike T. et al. International consensus statement on prelimi-nary classification criteria for definite anti-phospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42 (07) 1309-11.
30 Bili A, Moss AJ, Francis CW. et al. Anticardiolipin antibodies and recurrent coronary events: a prospective study of 1150 patients. Thrombogenic Factors, and Recurrent Coronary Events Investigators. Circulation 2000; 102 (11) 1258-63.
31 Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301 (02) 61-8.
32 Huber K, Rosc D, Resch I. et al. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb Haemost 1988; 60 (03) 372-6.
33 Kapiotis S, Jilma B, Quehenberger P. et al. Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex. Circulation 1997; 96 (01) 19-21.
34 Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989; 79 (01) 101-6.
35 Bridges AB, McLaren M, Scott NA. et al. Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating factor in men with ischaemic heart disease. Br Heart J 1993; 69 (02) 121-4.
36 Korninger C, Speiser W, Wojta J, Binder BR. Sandwich ELISA for t-PA antigen employing a monoclonal antibody. Thromb Res 1986; 41 (04) 527-35.
37 Kalunian KC, Peter JB, Middlekauff HR. et al. Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Am J Med 1988; 85 (05) 602-8.
38 Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987; 68 (01) 215-22.
39 Harris EN. Solid-phase anti-cardiolipin test revisited. Am J Med 1988; 85 (05) 599-601.
40 Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74 (01) 1-9.
41 Lewis MR, Callas PW, Jenny NS, Tracy RP. Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples. Thromb Haemost 2001; 86 (06) 1495-500.
42 Huber K, Jorg M, Probst P. et al. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a sig-nificantly reduced risk for coronary restenosis. Thromb Haemost 1992; 67 (02) 209-13.
43 Gottsauner-Wolf M, Sochor H, Hornykewycz S. et al. Predictive value of PAI-1 plasma activity and thallium perfusion imaging for restenosis after percutaneous transluminal angioplasty in clinically asymptomatic patients. Thromb Haemost 1999; 81 (04) 522-6.
44 Salomaa V, Stinson V, Kark JD. et al. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 1995; 91 (02) 284-90.
45 Gram J, Bladbjerg EM, Moller L. et al. Tissue-type plasminogen activator and C-reactive protein in acute coronary heart disease. A nested case-control study. J Intern Med 2000; 247 (02) 205-12.
46 Chandler WL, Alessi MC, Aillaud MF. et al. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 1997; 96 (03) 761-8.
47 Geppert A, Graf S, Beckmann R. et al. Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease. Arterioscler Thromb Vasc Biol 1998; 18 (10) 1634-42.
48 Chandler WL, Trimble SL, Loo SC, Mornin D. Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma. Blood 1990; 76 (05) 930-7.
49 Chia S, Ludlam CA, Fox KA, Newby DE. Acute systemic inflammation enhances endothelium-dependent tissue plasminogen activator release in men. J Am Coll Cardiol 2003; 41 (02) 333-9.
50 Paramo JA, Orbe J, Fernandez J. Fibrinolysis/proteolysis balance in stable angina pectoris in relation to angiographic findings. Thromb Haemost 2001; 86 (02) 636-9.
51 Steins MB, Padro T, Li CX. et al. Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries. Atherosclerosis 1999; 145 (01) 173-80.
52 Van Hinsberg VW, Sprengers ED, Kooistra T. Effect of thrombin on the production of plasminogen activators and PA inhibitor-1 by human foreskin microvascular endothelial cells. Thromb Haemost 1987; 57 (02) 148-53.
53 Bounameaux H, Kruithof EK. On the association of elevated tPA/PAI-1 complex and von Willebrand factor with recurrent myocardial infarction. Arterioscler Thromb Vasc Biol 2000; 20 (08) 1857-9.